Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Psilocybin is a serotonin receptor agonist with demonstrated therapeutic potential for treatment-resistant depression in humans.
• Investigating the efficacy of psilocybin in preclinical models is crucial for understanding its antidepressant mechanisms.

Purpose of the Study:

• To evaluate the antidepressant-like effects of psilocybin and its active metabolite, psilocin, in the Flinders Sensitive Line (FSL) rat model of depression.
• To determine if psilocybin or psilocin reduce immobility in the forced swim test (FST) and affect locomotor activity in the open field test (OFT).

Main Methods:

• Utilized the Flinders Sensitive Line (FSL) rat model, a validated model for depression.
• Administered psilocin and psilocybin at various doses and treatment paradigms.
• Assessed antidepressant-like effects using the forced swim test (FST) and controlled for stimulant properties with the open field test (OFT).

Main Results:

• Neither psilocin nor psilocybin demonstrated any significant antidepressant-like effect, evidenced by no reduction in immobility time in the FST.
• Locomotor activity in the open field test (OFT) was not affected by psilocin or psilocybin administration.
• As expected, FSL rats exhibited significantly more immobility compared to the Flinders Resistant Line (FRL) control group.

Conclusions:

• Psilocybin and psilocin did not produce antidepressant-like effects in the FSL rat model of depression.
• The findings contrast with the observed positive effects of psilocybin in human clinical trials for depression.
• Suggests the need for alternative animal models and behavioral assays for future translational research on psilocybin's antidepressant properties.